Larvol Delta - Cognition-Therapeuticsannounced-that-the-company-has-reached-target-enrollment-of-540-participants-in-the-randomized-placebocontrolled-Phase-2-START-Study

Elayta (zervimesine) - Cognition Therap

https://www.globenewswire.com/news-release/2025/11/13/3187212/0/en/Cognition-Therapeutics-Completes-Enrollment-in-Phase-2-Study-of-Zervimesine-CT1812-in-Early-Alzheimer-s-Disease.html

Nov 13, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next